Early-phase clinical trial data, including results from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023), demonstrated significant weight reduction in adults with obesity (without type 2 diabetes), with participants receiving the highest dose losing a mean of approximately 24% of their body weight over 48 weeks
GLP & GIP receptor agonist (Mounjaro) The active ingredient in Mounjaro is tirzepatide
Start your intake How Semaglutide Works for Weight Loss Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that signals fullness to your brain and slows stomach emptying
Ambos son los ltimos medicamentos para la obesidad con alta eficacia clnica
Glucose Homeostasis Studies Research has examined Retatrutides effects on postprandial and fasting glucose regulation in pre-clinical metabolic models studying how tri-receptor activation simultaneously influences insulin secretion, glucagon dynamics, gastric emptying, and hepatic glucose output to understand the full scope of its glucose-regulating activity
When clinically appropriate, your physician may pair semaglutide with testosterone replacement therapy, hormone therapy for women, or peptide therapy for muscle preservation and recovery